Market Access News | pharmaphorum

News

Imfinzi becomes first NHS drug for aggressive lung cancer

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.

News

RFK Jr expands ACIP ahead of highly anticipated meeting

Five members have been added to a controversial CDC vaccines panel ahead of a meeting this week that could have an impact on US immunisation policy.

News

Novo's oral GLP-1 is first to claim heart health label

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction.

News

AbbVie loses bid to block 340B law in Mississippi

Battle lines are being drawn on 340B rebates as AbbVie loses a bid to block a Mississippi law seeking to retain discounts for contract pharmacies.

News

AZ halts UK investment, and Lilly, Sanofi follow suit

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

Imfinzi becomes first NHS drug for aggressive lung cancer

RFK Jr expands ACIP ahead of highly anticipated meeting

Novo's oral GLP-1 is first to claim heart health label

AbbVie loses bid to block 340B law in Mississippi

AZ halts UK investment, and Lilly, Sanofi follow suit

Reaction to MSD's UK exit as government tries to renew talks

Lilly UK recruits ex-England cricketer as obesity champion

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks